American Association for Cancer Research

AACR in the News

Black Women Had Worse Breast Cancer Mortality Regardless of Cancer Subtype


April 6, 2013

Bookmark and Share

  • Black women had worse survival compared with other racial/ethnic groups.
  • They were more often diagnosed with less treatable cancer subtypes.
  • The survival difference was not attributable entirely to differential subtype diagnosis.
WASHINGTON, D.C. — Black women with breast cancer had significantly worse survival compared with other racial and ethnic groups across cancer subtypes, which suggests that the survival differences are not solely attributable to the fact that black women are more frequently diagnosed with less treatable breast cancer subtypes, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

“The results seem to indicate that although African-American women are more likely to be diagnosed with less treatable subtypes of breast cancer compared with white women, it is not the only reason they have worse breast cancer mortality,” said Candyce Kroenke, M.P.H., Sc.D., research scientist at Kaiser Permanente Division of Research in Oakland, Calif.

Kroenke and colleagues examined the link between race and breast cancer survival in a prospective cohort of 1,688 breast cancer survivors enrolled in the Life After Cancer Epidemiology and Pathways study. The survivors had been treated for luminal A, luminal B, basal-like or HER2-enriched breast cancer.

The researchers obtained participants’ self-reported race information from mailed questionnaires. They tested samples of the patients’ tumors to determine their molecular subtype of cancer.

After 6.3 years of follow-up, 499 women had died, 268 of them from breast cancer. Consistent with previous data, black women were nearly two times more likely to have died from breast cancer compared with white women. In addition, black women were less likely to be diagnosed with either the luminal A or luminal B breast cancer subtypes compared with white women.

“African-Americans were more likely to have the hard-to-treat triple-negative breast cancer subtype and had a lower likelihood of having the luminal A subtype, which tends to be the most treatable subtype of breast cancer and has the best prognosis,” Kroenke said.

However, the researchers found that poor prognosis among blacks appeared consistent across breast cancer subtypes. Compared with white women, black women were 2.3 times more likely to die from the luminal A breast cancer subtype, 2.6 times more likely to die from the luminal B subtype, 1.3 times more likely to die from the basal-like subtype and 2.4 times more likely to die from the HER2-enriched subtype.

“African-Americans with breast cancer appeared to have a poorer prognosis regardless of subtype,” Kroenke said. “It seems from our data that the black–white breast cancer survival difference cannot be explained entirely by variable breast cancer subtype diagnosis.”

# # #

Press registration for the AACR Annual Meeting 2013 is free to qualified journalists and public information officers.

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.

Media Contact:
Jeremy Moore
(215) 446-7109
Jeremy.Moore@aacr.org
In Washington, D.C.,
April 6-10, 2013:

(202) 249-4005